PANX1 and melanoma: Besides, the germline deletion of Panx1 does not necessarily imply the same effect previously observed with the use of PANX1 channel blockers (e.g., with carbenoxolone, probenecid, or spironolactone) due to possible compensation with other proteins (e.g., connexins or other paralogs) yet to be tested using this or another in vivo melanoma model.